[Current TNM/FIGO classification for cervical and endometrial cancer as well as malignant mixed müllerian tumors. Facts and background]
- PMID: 20084383
- DOI: 10.1007/s00292-010-1273-6
[Current TNM/FIGO classification for cervical and endometrial cancer as well as malignant mixed müllerian tumors. Facts and background]
Abstract
Numerous recent studies of endometrial and cervical carcinomas as well as malignant mixed müllerian tumors (MMMT) of the uterus have made a revision of the FIGO/TNM classification necessary, effective as of January 1st, 2010. There will be a new subclassification of carcinoma of the uterine cervix with proximal vaginal infiltration, using the same cut-off for the tumor extension as used for stage FIGOIB/T1b (≤/>4 cm), resulting in stage FIGO IIA1/T2a1 and FIGO IIA2/T2a2. In endometrial carcinoma, the previous FIGO IA/pT1a and FIGO IB/pT1b will be merged to FIGO IA/pT1a. The former category FIGO IC/T1c will be changed into FIGO IB/T1b. The category FIGO IC/pT1c will not longer been used. Additionally, there will be no separate classification for the involvement of the endocervical glands by endometrial carcinoma. This feature will be incorporated in stage FIGO I/T1 disease. The new category FIGO II/T2 will be defined as endocervical stromal involvement. There will be a new category, termed T3c/IIIC, which includes regional lymph node involvement. Stage T3c1/IIIC1 will be defined as pelvic lymph node involvement and stage T3c2/IIIC2 para-aortal lymph node involvement with or without pelvic lymph node disease. In the TNM system, regional lymph node involvement can alternatively be classified as N1. The MMMT will be staged like endometrial carcinoma.
Similar articles
-
[The 2019 FIGO classification for cervical carcinoma-what's new?].Pathologe. 2019 Nov;40(6):629-635. doi: 10.1007/s00292-019-00675-w. Pathologe. 2019. PMID: 31612260 Review. German.
-
[Changes in the TNM classification of gynecological tumors].Pathologe. 2010 Sep;31(5):367-73. doi: 10.1007/s00292-010-1308-z. Pathologe. 2010. PMID: 20844876 German.
-
The prognostic value of the presence of pelvic and/or para-aortic lymph node metastases in cervical cancer patients; the influence of the new FIGO classification (stage IIIC).Gynecol Oncol. 2023 Apr;171:9-14. doi: 10.1016/j.ygyno.2023.01.023. Epub 2023 Feb 16. Gynecol Oncol. 2023. PMID: 36804623
-
FIGO staging of endometrial cancer: 2023.Int J Gynaecol Obstet. 2023 Aug;162(2):383-394. doi: 10.1002/ijgo.14923. Epub 2023 Jun 20. Int J Gynaecol Obstet. 2023. PMID: 37337978
-
[Metastatic mechanisms of uterine malignancies and therapeutic consequences].Pathologe. 2016 Nov;37(6):549-556. doi: 10.1007/s00292-016-0243-z. Pathologe. 2016. PMID: 27757531 Review. German.
Cited by
-
Radiographic Number of Positive Pelvic Lymph Nodes as a Prognostic Factor in Cervical Cancer Treated With Definitive Concurrent Chemoradiotherapy or Intensity-Modulated Radiotherapy.Front Oncol. 2018 Nov 30;8:546. doi: 10.3389/fonc.2018.00546. eCollection 2018. Front Oncol. 2018. PMID: 30555798 Free PMC article.
-
Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015).Geburtshilfe Frauenheilkd. 2015 Oct;75(10):1028-1042. doi: 10.1055/s-0035-1558120. Geburtshilfe Frauenheilkd. 2015. PMID: 26640293 Free PMC article.
-
[The 2019 FIGO classification for cervical carcinoma-what's new?].Pathologe. 2019 Nov;40(6):629-635. doi: 10.1007/s00292-019-00675-w. Pathologe. 2019. PMID: 31612260 Review. German.
-
The involvement of E6, p53, p16, MDM2 and Gal-3 in the clinical outcome of patients with cervical cancer.Oncol Lett. 2017 Oct;14(4):4467-4476. doi: 10.3892/ol.2017.6752. Epub 2017 Aug 14. Oncol Lett. 2017. PMID: 29085443 Free PMC article.
-
Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018).Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1060-1078. doi: 10.1055/a-0919-4959. Epub 2019 Jul 16. Geburtshilfe Frauenheilkd. 2019. PMID: 31680701 Free PMC article.